A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum

Simply Wall St.04-14

AdvertisementWhy Catalyst Pharmaceuticals Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn fresh attention after recent trading, with the share price closing at $25.34. Investors are ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627941990?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-14 16:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627941990","market":"sg","top_or_hot":-1,"title":"A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Catalyst Pharmaceuticals Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn fresh attention after recent trading, with the share price closing at $25.34. Investors are ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-rece\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-14 16:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-rece><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Catalyst Pharmaceuticals Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn fresh attention after recent trading, with the share price closing at $25.34. Investors are ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-rece\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-rece","article_id":"2627941990","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/a-look-at-catalyst-pharmaceuticals-cprx-valuation-after-rece","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627941990","pubTimestamp":1776154300,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Catalyst Pharmaceuticals Is On Investors’ Radar\nCatalyst Pharmaceuticals (CPRX) has drawn fresh attention after recent trading, with the share price closing at $25.34. Investors are weighing this level against the company’s current earnings profile and rare disease focus.\nSee our latest analysis for Catalyst Pharmaceuticals.\nThe 1-day share price return of 1.6% builds on a 30-day share price return of 9.1% and a three year total shareholder return of 40.2%, pointing to momentum that has...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","BK4139":"生物科技","CPRX":"Catalyst Pharmaceutical Partners","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D"},"translate_title":"近期股价势头后看看Catalyst Pharmaceuticals(CPRX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"CPRX":1.5},"content_text":"AdvertisementWhy Catalyst Pharmaceuticals Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn fresh attention after recent trading, with the share price closing at $25.34. Investors are weighing this level against the company’s current earnings profile and rare disease focus. See our latest analysis for Catalyst Pharmaceuticals. The 1-day share price return of 1.6% builds on a 30-day share price return of 9.1% and a three year total shareholder return of 40.2%, pointing to momentum that has attracted more attention to how the current price lines up with earnings and rare disease assets. If this kind of move has you looking beyond a single name, it can be useful to scan for other healthcare names with specialized growth stories using our 34 healthcare AI stocks With a US$3.0b market cap, US$589.0m in revenue, US$214.3m in net income and a value score of 6, the question is simple: is Catalyst still attractively priced or is the market already baking in future growth? Price-to-Earnings of 14.4x: Is It Justified? On a P/E of 14.4x, Catalyst Pharmaceuticals screens as good value relative to its own estimated fair P/E of 14.8x, its peers and the wider US Biotechs industry, given the last close at $25.34. The P/E ratio compares the current share price to earnings per share, so it effectively shows how much investors are paying for each dollar of earnings. For a commercial stage rare disease company with $588.989m in revenue, $214.326m in net income and a focus on approved therapies, this yardstick helps you judge whether the market is putting a premium or a discount on those earnings. Here, the 14.4x P/E sits below the estimated fair P/E of 14.8x. This indicates the valuation is slightly under that fair value level the market could move toward if sentiment stays aligned with current earnings quality. It also sits below the US Biotechs industry average P/E of 17.7x and well below the peer average P/E of 29.6x. This gap highlights how cautiously the market is pricing the rare disease earnings stream relative to many biotech names. Explore the SWS fair ratio for Catalyst Pharmaceuticals Result: Price-to-Earnings of 14.4x (UNDERVALUED) However, that picture can shift quickly if rare disease demand proves less resilient than expected, or if competition and pricing pressure weigh on earnings visibility. Find out about the key risks to this Catalyst Pharmaceuticals narrative. Another View: What The Cash Flows Say While the 14.4x P/E hints at a modest discount, the SWS DCF model is far more aggressive, putting future cash flow value at $63.30 per share versus the current $25.34. That gap suggests either a large opportunity or a model that is too optimistic. Which side do you think is closer to reality? Look into how the SWS DCF model arrives at its fair value. CPRX Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Catalyst Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Given the mix of cautious and optimistic signals around Catalyst, it makes sense to look at the data yourself and decide where you stand. If you want a clearer picture of what the market is excited about right now, take a closer look at the company's 5 key rewards Ready For More Investment Ideas? If you stop with just one stock, you may miss opportunities that fit your goals even better, so widen your search with a few focused stock ideas.  Target potential mispricings by scanning 55 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their current financial profile. Strengthen your income stream by reviewing 10 dividend fortresses built around companies offering yields above 5% while aiming to maintain stability. Protect your downside by checking 73 resilient stocks with low risk scores that stand out for resilient balance sheets and lower overall risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627941990","isCrawlerRequest":true}